assistant professor, cancer immunologist, bioinformatics and cancer genomics
Joined December 2020
- Tweets 75
- Following 86
- Followers 58
- Likes 24
Photos and videos
Vladimir Roudko retweeted
25 Sep 2023
Just heard the brilliant news that AlphaFold was awarded the lasker award- congratulation to Deemis Hassabis & team for a well deserved recognition laskerfoundation.org/winners…
1
9
51
7,152
Today we launch the next generation of AI oncology company with the support of great investors @hardimanjames @DCVC, @dreidco @ZettaVentures, 11.2, Intermountain Ventures, Epic Ventures, Catalio, North South Ventures, @viswacolluru @RecursionChris.
businesswire.com/news/home/2…
7
12
56
9,378
Vladimir Roudko retweeted
8 Apr 2023
New generation of cancer-preventing vaccines enter early clinical trials for healthy people at high risk for disease #cancer #Immunotherapy
science.org/content/article/…
53
103
13,468
Vladimir Roudko retweeted
30 Jun 2022
Storing and analyzing a genome on a blockchain genomebiology.biomedcentral.…
1
31
136
Vladimir Roudko retweeted
11 Feb 2022
The @bernstein_lab is now on #Twitter! Follow us for lab updates and news on cancer epigenetics!!
🧬🔬
7
19
162
Vladimir Roudko retweeted
10 Feb 2022
New updated analysis by the team at @CancerResearch in collaboration with @IQVIA_global of the PD1/PDL1 clinical trial landscape, including use of approved therapies in the clinic and a summary of new anti-PD1/PDL1 treatment modalities go.nature.com/3HIpHPm
22
52
7 Feb 2022
Great news!
.@MountSinaiNYC has announced a transformative multimillion-dollar gift from Marc Lipschultz, who serves on Mount Sinai’s Boards of Trustees, and his wife, Jennifer, to the Precision Immunology Institute (PrIISM) at @IcahnMountSinai: mshs.co/2uR
1
The new @EMBL Programme has launched!
We're proud to be a part of @EMBL and we're looking forward to contributing our #bioinformatics expertise to this exciting new scientific programme that ushers in a new era in the life sciences.
EMBL embarks on a new era of molecular biology.
EMBL research will expand to study life in context – from molecules to ecosystems. Broad in scope, our next programme encompasses fundamental research, services & multidisciplinary collaboration.
embl.org/news/lab-matters/a-…
2
21
83
Vladimir Roudko retweeted
18 Jan 2022
A study evaluating effectiveness of the BNT162b2 (Pfizer-BioNTech) vaccine against the #Omicron variant indicates a third dose neutralizes Omicron at a similar order of magnitude as was observed after two doses of the vaccine against wild-type #SARSCoV2. fcld.ly/d9noexp
8
113
185
18 Jan 2022
Specialized ribosomes go immune! Role of protein translation in immunotherapy response and evasion gets first recognition.
17 Jan 2022
Group leaders Pia Kvistborg and William Faller received an ASPIRE award from the Mark Foundation. With it, they can dive into a brand new research field, chasing down ribosomes - the protein factories in the cells that may be sabotaging immunotherapy ➡️ bit.ly/3nyak46
1
Vladimir Roudko retweeted
MEFISTO is out in Nature Methods - a framework for dimension reduction and integration of multi-modal omics data with temporal or spatial resolution. Paper at nature.com/articles/s41592-0…, highlights in the thread below. (1/7)
10
112
423
Vladimir Roudko retweeted
13 Jan 2022
(1) Finally out, after one of the most painful and long reviews (with nitpicky reviews, see my last comment) is a method that I am extremely proud of and excited about. One of the best in my career: nature.com/articles/s41592-0…
24
274
1,269
13 Jan 2022
How does that even make any sense?
11 Jan 2022
In this scenario, the cost of publication is covered by an Article Processing Charge (APC) paid at the time of publication. The APC for Nature Neuroscience in 2022 is €9,500/US $11,390/£8,290.
Vladimir Roudko retweeted
30 Dec 2021
Excited to share my work from @DASLab_MSKCC lab out today in @nchembio where we develop CAR-T cells that produce small molecule drugs at the tumor site. This is an exciting step forward in the utilization of engineered cells for drug delivery! nature.com/articles/s41589-0…
22
78
317
Vladimir Roudko retweeted
29 Dec 2021
Studying ~56 million T cells from 55 COVID patients, researchers in @SciImmunology offer a high-res picture of epitope reactivity and TCR usage in CD8 T cells specific for #SARSCoV2, some of which also react to “common cold” coronaviruses. fcld.ly/s5bda4r
1
41
141
Vladimir Roudko retweeted
28 Dec 2021
Highly recommended review! 🤯😍😍👏
Germinal Centre Shutdown frontiersin.org/article/10.3…
6
5
Vladimir Roudko retweeted
28 Dec 2021
A new method developed to reread a single polypeptide many times overcomes one of the biggest obstacles toward single-molecule proteomics.
Read more in a new #SciencePerspective: fcld.ly/23d7ov4
51
238
Vladimir Roudko retweeted
27 Dec 2021
Findings from the KEYNOTE-522 trial show the addition of the immunotherapy agent pembrolizumab to chemotherapy before surgery decreased the recurrence by almost 40% in patients with early triple-negative breast cancer. #TNBC
bit.ly/3yXPUGd
2
4
Vladimir Roudko retweeted
22 Dec 2021
Protein modifications throughout the lung cancer proteome unravel the cancer-specific regulation of glycolysis dlvr.it/SFrY1K
1
11
32